Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Pavel, Marianne; Ćwikła, Jarosław B.; Lombard‐Bohas, Catherine; Borbath, Ivan; Shah, Tahir; Pape, Ulrich Frank; Capdevila, Jaume; Panzuto, Francesco; Thanh, Xuan-Mai Truong; Houchard, Aude; Ruszniewski, Philippe

doi:10.1016/j.ejca.2021.06.056

Cited by 51 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 In the CLARINET FORTE study, only 22.7% of the PanNET patients had a CgA level > ULN. 7 For non-functional PanNET pancreatic polypeptide (PP) could be used to assist in the diagnosis of the disease. [8][9][10] The sensitivity for PP in metastatic disease is in the range 50-80%.…”

Section: Introductionmentioning

confidence: 99%

“…An analysis from the CLARINET study demonstrated that, at the time of diagnosis, only 49% and 26% of patients with PanNET had a higher than upper limit of normal (ULN) levels of CgA and 5‐HIAA, respectively 6 . In the CLARINET FORTE study, only 22.7% of the PanNET patients had a CgA level > ULN 7 . For non‐functional PanNET pancreatic polypeptide (PP) could be used to assist in the diagnosis of the disease 8–10 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors

Schalin‐Jäntti

Schneider

Thiis‐Evensen³

et al. 2022

J Neuroendocrinology

View full text Add to dashboard Cite

There is an unmet need for novel biomarkers to diagnose and monitor patients with neuroendocrine neoplasms. The EXPLAIN study explores a multi-plasma protein and supervised machine learning strategy to improve the diagnosis of pancreatic neuroendocrine tumors (PanNET) and differentiate them from small intestinal neuroendocrine tumors (SI-NET). At time of diagnosis, blood samples were collected and analyzed from 39 patients with PanNET, 135 with SI-NET (World Health Organization Grade 1-2) and 144 controls. Exclusion criteria were other malignant diseases, chronic inflammatory diseases, reduced kidney or liver function. Prosed Oncology-II (i.e., OLink) was used to measure 92 cancer related plasma proteins. Chromogranin A was analyzed separately.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors

Schalin‐Jäntti

Schneider

Thiis‐Evensen³

et al. 2022

J Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Some important clinical studies, including the PROMID[ 84 ] and CLARINET[ 85 ] trials, have demonstrated a significant efficacy of SSA in the control of tumor growth in patients with metastatic GEP-NETs. A recent CLARINET FORTE phase 2 clinical trial further supports the clinical benefit of the SSA lanreotide autogel (LAN), which led to significantly improved progression-free survival (PFS) and disease control rate in patients with GEN-NETs, especially in cases with a Ki67 index ≤ 10%[ 86 ]. In addition to SSA[ 87 ], novel therapeutic approaches, including PRRT, targeted therapy, and immunotherapy, have demonstrated promising clinical benefits[ 88 - 90 ].…”

Section: Novel Therapeutic Approachesmentioning

confidence: 99%

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Yin¹,

Wu²,

Lai³

2022

WJG

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare epithelial neoplasms derived from pluripotent endocrine cells along the gastrointestinal tract and pancreas. GEP-NENs are classified into well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Despite overlapping morphological features, GEP-NENs vary in molecular biology, epigenetic, clinical behavior, treatment response, and prognosis features and remain an unmet clinical challenge. In this review, we introduce recent updates on the histopathologic classification, including the tumor grading and staging system, molecular genetics, and systemic evaluation of the diagnosis and treatment of GEP-NENs at different anatomic sites, together with some insights into the diagnosis of challenging and unusual cases. We also discuss the application of novel therapeutic approaches for GEP-NENs, including peptide receptor radionuclide therapy, targeted therapy, and immunotherapy with immune checkpoint inhibitors. These findings will help improve patient care with precise diagnosis and individualized treatment of patients with GEP-NENs.

show abstract

“…Although not routine, emerging data suggest that treatment with SSAs may be appropriate beyond progression with dose intensification. 15,50 In short, low-volume disease presents a unique challenge given a lack of data to guide therapy decisions and the potential for toxicities in patients who might otherwise have a relatively good prognosis.…”

Section: Low-volume Diseasementioning

confidence: 99%

Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Hope

Pavel

Bergsland

2022

JCO

Self Cite

View full text Add to dashboard Cite

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, the only approved agent, is indicated for the treatment of gastroenteropancreatic-neuroendocrine tumors. Although patient selection appears straightforward with somatostatin receptor-positron emission tomography, there is considerable complexity when deciding which patients to treat and when to start PRRT. Herein, we review the many factors that affect patient selection, focusing on the optimal patients to treat. Although significant effort has been expended to determine which patients benefit the most from PRRT, a validated predictive biomarker remains elusive. Although PRRT has been used for more than 2 decades in Europe and standards of care exist for safe treatment, there remain numerous questions regarding when PRRT should be used relative to other treatments. It is important to remember that multidisciplinary discussions are essential. Currently, there are a number of ongoing studies looking to assess the efficacy of PRRT compared with other treatment options and to optimize treatment through combination therapy, different dosing strategies, or use of different radionuclides and radioligands.

show abstract

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Cited by 51 publications

References 23 publications

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors

New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Contact Info

Product

Resources

About